Ishara Investments LP Takes $1.16 Million Position in Denali Therapeutics Inc. $DNLI

Ishara Investments LP purchased a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI) in the 4th quarter, HoldingsChannel.com reports. The firm purchased 70,000 shares of the company’s stock, valued at approximately $1,156,000. Denali Therapeutics accounts for approximately 1.3% of Ishara Investments LP’s holdings, making the stock its 25th biggest position.

Other hedge funds also recently made changes to their positions in the company. Foresite Capital Management VI LLC purchased a new position in shares of Denali Therapeutics in the third quarter valued at $14,520,000. Aberdeen Group plc grew its position in shares of Denali Therapeutics by 23.4% in the third quarter. Aberdeen Group plc now owns 1,113,586 shares of the company’s stock valued at $16,169,000 after purchasing an additional 210,835 shares in the last quarter. Capricorn Fund Managers Ltd purchased a new position in shares of Denali Therapeutics in the fourth quarter valued at $1,027,000. Holocene Advisors LP grew its position in shares of Denali Therapeutics by 677.8% in the third quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock valued at $45,531,000 after purchasing an additional 2,732,540 shares in the last quarter. Finally, Baillie Gifford & Co. grew its position in shares of Denali Therapeutics by 6.2% in the fourth quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock valued at $203,253,000 after purchasing an additional 719,304 shares in the last quarter. 92.92% of the stock is currently owned by hedge funds and other institutional investors.

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $23.49 on Thursday. Denali Therapeutics Inc. has a 52 week low of $12.58 and a 52 week high of $24.21. The business has a 50-day simple moving average of $19.94 and a 200 day simple moving average of $19.52. The company has a quick ratio of 9.28, a current ratio of 9.28 and a debt-to-equity ratio of 0.01. The stock has a market cap of $3.73 billion, a price-to-earnings ratio of -8.16 and a beta of 1.03.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Thursday, May 7th. The company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.04. During the same period in the previous year, the firm earned ($0.78) EPS. On average, research analysts forecast that Denali Therapeutics Inc. will post -2.77 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DNLI has been the subject of several recent research reports. HC Wainwright lifted their price target on Denali Therapeutics from $32.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Wall Street Zen upgraded Denali Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 9th. Deutsche Bank Aktiengesellschaft set a $31.00 price target on Denali Therapeutics in a research report on Friday, May 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Monday, April 20th. Finally, Leerink Partners reduced their price target on Denali Therapeutics from $40.00 to $35.00 and set an “outperform” rating for the company in a research report on Wednesday, April 22nd. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $34.25.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.